Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status
| Autor: | François Helle, Julien Moyet, Baptiste Demey, Catherine François, Gilles Duverlie, Sandrine Castelain, Fréderic Bloch, Etienne Brochot |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Vaccines
COVID-19 Vaccines General Veterinary General Immunology and Microbiology SARS-CoV-2 Public Health Environmental and Occupational Health COVID-19 Antibodies Viral Antibodies Neutralizing Article Immunity Humoral Nursing Homes Infectious Diseases Spike Glycoprotein Coronavirus Humans Molecular Medicine Serological assay Humoral vaccine response Aged |
| Zdroj: | Vaccine |
| ISSN: | 0264-410X |
| Popis: | Background Coronavirus disease 2019 (COVID-19) is associated with increased morbidity and mortality in older adults. Although the advent of the first vaccines has significantly reduced these rates, data on older adults in clinical trials are scarce. Objectives We quantified and compared the humoral response in individuals with vs. without pre-existing seropositivity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in a cohort of 69 patients living in a nursing home and who had received the recommended two doses of the Comirnaty (Pfizer-BioNTech®) vaccine. Results All 69 patients (100%) tested positive for antibodies against SARS-CoV-2 at 2 months post-vaccination. Residents with a pre-vaccination infection had significantly higher titers of anti-spike 1 IgG than those with no prior infection (median [interquartile range]: 55,726 [14463–78852] vs. 1314 [272–1249] arbitrary units, respectively; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect